The Pfizer Clinical Research Unit in New Haven is conducting a clinical trial of an oral study drug for atopic dermatitis (eczema). This trial will look at the effects of the study drug when given to adult female participants alongside other medications.
Atopic dermatitis (AD) is one of the most common chronic inflammatory skin conditions. It causes a rash and itching and can negatively affect patients’ emotional well-being. There is no cure for AD and while available treatments may provide symptom relief, the community needs new long-term treatment options.
Learn how you can support patients as a healthy volunteer below.
Who may participate
When you make the choice to participate, you represent your community and help patients like you from around the world.
This study is seeking healthy adult volunteers, meaning that the participants will not have the condition being studied and are in overall good health. Healthy volunteers are a vital part of medical discovery and help build the foundations for further research.
In addition to the criteria listed, participants must meet the following requirements:
- Willing to take a study drug
- Willing and able to come to our facility in New Haven, CT*
- Willing and able to comply with all study procedures
- Are not currently using hormonal contraception (birth control)
*participants may be eligible to receive a bonus for travel, ask our staff for details
There are other requirements for participation in this study. The study staff will explain these to you during the screening process.
Do you know someone who may meet these requirements? Refer a friend and you may be eligible to receive a bonus.
Condition
Healthy
Age
18+ years
Sex
Female
Referral bonus
Up to $200
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.
What to expect
If this study may be a fit for you, you’ll be invited to a screening visit at our facility in New Haven, CT. If you qualify for the study, there may be a period of up to 28 days before dosing.
If you choose to participate, you will stay at our facility for 24 consecutive overnights. Starting about a week after you arrive, you will receive twice-daily doses of the study drug for up to 17 days. In addition, throughout the study you will receive oral doses of up to 3 different medications that are being used in combination with the study drug. You will receive each of these medications at least once by themselves (prior to dosing with the study drug), and up to 2 additional times combined with the study drug.
All doses will be provided as tablets, capsules, or liquids to swallow and may be given with or without food. The exact schedule for dosing will be shared with you during screening and can be reviewed in the informed consent document (ICD).
Throughout the study, staff will closely monitor your health status and collect data, such as the levels of the study drug in your blood.
Required overnight stays
24 consecutive overnights
Long-term follow up
1 phone call
How long is this study?
About 51 days
Compensation
Up to $10,900 upon completion of the study
All of the study procedures will be clearly explained to you during screening and can be viewed in the informed consent form.
The PCRU Loyalty Program has arrived!
Our new Loyalty Program offers unique tiered gifts for new and returning participants.
Interested in participating?
Complete and submit this form, and a Pfizer New Haven Clinical Research Unit (PCRU) representative will contact you.
You may also call 1-800-254-6398 and speak with a PCRU representative to learn more.
For Japanese language assistance only, please call 1-833-711-9984.
The personal data gathered here will be collected, processed, and maintained in a confidential manner. Your information will be stored in our research unit’s database. We may use this information to invite you to participate in current and future clinical studies at the PCRU. You will have full access to your records at the Pfizer New Haven Clinical Research Unit and the opportunity to correct them if necessary.